InflaRx Vision and Strategy

InflaRx is focused on developing its proprietary anti-C5a technology while broadening and diversifying the R&D pipeline. Specifically, InflaRx will:
 

• Continue to development of our anti-C5a technology with Vilobelimab 
   
• • Hidradenitis Suppurativa: Initiate Phase III program incorporating novel endpoint
  • Pyoderma Gangrenosum: Advance towards Phase III based on regulatory guidance
  • Severe COVID-19: Complete Phase III and submit for approval if results are positive
  • Anca-Associated Vasculitis: Discuss next steps with regulatory authorities
  • Oncology: Continue to explore clinical applications
     
• Advance INF904 into first-in-human studies
• Continue to explore broadening the R&D pipeline beyond anti-C5a technology as part of a diversification strategy